Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott L Friedman

Showing results (61-70 of 388) with videos related to

Pageof 39
Sort By:
Hepatology (Baltimore, Md.)|February 1, 2020
Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell DeactivationShuang Wang, Scott L Friedman
Current Opinion in Pharmacology|October 8, 2019
New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseasesSara Lemoinne, Scott L Friedman
Current Pharmaceutical Design|October 25, 2012
The expression patterns and clinical significance of microRNAs in liver diseases and hepatocellular carcinomaJinsheng Guo, Scott L Friedman
Methods in Molecular Biology (Clifton, N.J.)|May 29, 2023
Working with Immortalized Hepatic Stellate Cell LinesScott L Friedman, Ralf Weiskirchen
Frontiers in Bioscience (Scholar Edition)|January 2, 2013
Cellular basis of hepatic fibrosis and its role in inflammation and cancerPeri Kocabayoglu, Scott L Friedman
Medgenmed : Medscape General Medicine|December 6, 2002
Hepatic fibrosis--role of hepatic stellate cell activationRifaat Safadi, Scott L Friedman
Journal of Hepatology|September 9, 2014
Focusing on the past, present, and future of hepatologyDaniel Shouval, Scott L Friedman
Hepatology (Baltimore, Md.)|December 19, 2021
Hepatic fibrosis 2022: Unmet needs and a blueprint for the futureScott L Friedman, Massimo Pinzani
Gastroenterology|May 23, 2020
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?Vlad Ratziu, Scott L Friedman
Science Translational Medicine|October 4, 2023
Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)Shuang Wang, Scott L Friedman
Pageof 39

Showing results (61-70 of 388) with videos related to

Sort By:
Pageof 39
Hepatology (Baltimore, Md.)|February 1, 2020
Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell DeactivationShuang Wang, Scott L Friedman
Current Opinion in Pharmacology|October 8, 2019
New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseasesSara Lemoinne, Scott L Friedman
Current Pharmaceutical Design|October 25, 2012
The expression patterns and clinical significance of microRNAs in liver diseases and hepatocellular carcinomaJinsheng Guo, Scott L Friedman
Methods in Molecular Biology (Clifton, N.J.)|May 29, 2023
Working with Immortalized Hepatic Stellate Cell LinesScott L Friedman, Ralf Weiskirchen
Frontiers in Bioscience (Scholar Edition)|January 2, 2013
Cellular basis of hepatic fibrosis and its role in inflammation and cancerPeri Kocabayoglu, Scott L Friedman
Medgenmed : Medscape General Medicine|December 6, 2002
Hepatic fibrosis--role of hepatic stellate cell activationRifaat Safadi, Scott L Friedman
Journal of Hepatology|September 9, 2014
Focusing on the past, present, and future of hepatologyDaniel Shouval, Scott L Friedman
Hepatology (Baltimore, Md.)|December 19, 2021
Hepatic fibrosis 2022: Unmet needs and a blueprint for the futureScott L Friedman, Massimo Pinzani
Gastroenterology|May 23, 2020
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?Vlad Ratziu, Scott L Friedman
Science Translational Medicine|October 4, 2023
Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)Shuang Wang, Scott L Friedman
Pageof 39